Antibody Discovery with Our Library of Phage Display Libraries

Quickly generate high-diversity, high quality molecules inspired by the human repertoire

Contact Us


Browse Our Library of Libraries

Drug the Undruggable

We’re writing the future of biologics discovery with a best-in-class platform, our library of phage display libraries (known as the “Library of Libraries”), for hard-to-drug targets.

Downstream Liabilities Removed

Focused Sequence Space

Broad Array of Libraries

Expand Your Discovery Opportunities

Expand Your Discovery Opportunities

Our pre-constructed, validated phage display libraries are built using our precision DNA writing technology, allowing us to remove motifs that can lead to downstream manufacturing liabilities and focus only on the applicable sequence space. Twist Biopharma has designed multiple general, naïve, and target-focused libraries with diversities ~1010, giving you a multifaceted approach to your next discovery project.

Antibody Discovery in As Little As a Few Months

Our collection of off-the-shelf libraries enable you to quickly identify high-quality leads against your target of interest using multiple strategies in only a few months. Select from libraries containing naïve human diversity, rationally designed with antibody structural considerations, or with diversity computationally tailored to high-value targets, including carbohydrates, hyperimmune, and structural motifs. They’re available in a variety of VHH, Fab, and scFv frameworks. These libraries can also be leveraged to develop monoclonal antibodies, multi-specifics, and chimeric antigen receptors (CARs) for CAR-T cell therapy.

Antibody Discovery in As Little As a Few Months
Watch the Webinar

Watch the Webinar

Developing Therapeutics Against Virtually Any Target with New Antibody Libraries

Watch it

What Scientists Have to Say

Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
Robert Carnahan, PhD
Associate Director of the Vanderbilt Vaccine Center